JPMorgan Chase & Co. reaffirmed their hold rating on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research note released on Wednesday morning, AnalystRatings.com reports. The brokerage currently has a $29.00 target price on the stock.
ALLO has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Allogene Therapeutics from a buy rating to a hold rating in a research note on Monday, August 12th. ValuEngine raised shares of Allogene Therapeutics from a sell rating to a hold rating in a research note on Friday, November 1st. Canaccord Genuity started coverage on shares of Allogene Therapeutics in a research note on Monday, November 4th. They set a buy rating and a $36.00 target price for the company. William Blair reaffirmed a buy rating on shares of Allogene Therapeutics in a research note on Tuesday, November 5th. Finally, BTIG Research initiated coverage on shares of Allogene Therapeutics in a research report on Friday, August 9th. They set a buy rating and a $37.00 price target for the company. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Allogene Therapeutics presently has an average rating of Buy and an average target price of $36.11.
Shares of Allogene Therapeutics stock traded up $0.88 during trading on Wednesday, hitting $27.32. The stock had a trading volume of 577,200 shares, compared to its average volume of 416,218. Allogene Therapeutics has a 12 month low of $23.37 and a 12 month high of $33.96. The business’s 50-day moving average is $27.85 and its 200 day moving average is $28.07. The firm has a market cap of $3.37 billion and a price-to-earnings ratio of -4.15. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.05.
In related news, insider Alison Moore sold 48,827 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $32.11, for a total transaction of $1,567,834.97. 36.50% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC boosted its holdings in Allogene Therapeutics by 3,789.2% in the third quarter. Tower Research Capital LLC TRC now owns 2,878 shares of the company’s stock worth $78,000 after purchasing an additional 2,804 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Allogene Therapeutics in the third quarter worth approximately $1,046,000. Creative Planning boosted its holdings in Allogene Therapeutics by 4.0% in the third quarter. Creative Planning now owns 26,000 shares of the company’s stock worth $709,000 after purchasing an additional 1,000 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Allogene Therapeutics in the third quarter worth approximately $996,000. Finally, Oppenheimer & Co. Inc. boosted its holdings in Allogene Therapeutics by 83.3% in the third quarter. Oppenheimer & Co. Inc. now owns 18,700 shares of the company’s stock worth $510,000 after purchasing an additional 8,500 shares during the last quarter. 54.48% of the stock is owned by institutional investors.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Read More: What is a bull market?
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.